These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 35476018)
21. Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. Šmíd M; Berec L; Přibylová L; Májek O; Pavlík T; Jarkovský J; Weiner J; Barusová T; Trnka J J Infect Dis; 2022 Oct; 226(8):1385-1390. PubMed ID: 35482442 [TBL] [Abstract][Full Text] [Related]
22. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study. Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808 [TBL] [Abstract][Full Text] [Related]
26. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
27. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. Chalupka A; Richter L; Chakeri A; El-Khatib Z; Theiler-Schwetz V; Trummer C; Krause R; Willeit P; Benka B; Ioannidis JPA; Pilz S Eur J Clin Invest; 2024 Mar; 54(3):e14136. PubMed ID: 38032853 [TBL] [Abstract][Full Text] [Related]
29. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Safdar S; Ngonghala CN; Gumel AB Math Biosci Eng; 2023 Jan; 20(1):179-212. PubMed ID: 36650762 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z; EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435 [TBL] [Abstract][Full Text] [Related]
31. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S Front Immunol; 2022; 13():876533. PubMed ID: 35711413 [TBL] [Abstract][Full Text] [Related]
32. [Clinical features of 19 children infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Hangzhou, China]. Qi ZH; Bei ZF; Teng S; Wang HP; Li W; Zhao SY; Liu SR Zhongguo Dang Dai Er Ke Za Zhi; 2022 Oct; 24(10):1092-1097. PubMed ID: 36305108 [TBL] [Abstract][Full Text] [Related]
33. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021. Hatfield KM; Baggs J; Wolford H; Fang M; Sattar AA; Montgomery KS; Jin S; Jernigan J; Pilishvili T Clin Infect Dis; 2022 Oct; 75(Suppl 2):S147-S154. PubMed ID: 35856635 [TBL] [Abstract][Full Text] [Related]
35. The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Tonnara G; Piselli P; Cimaglia C; Arlotti M; Sacchini E; Manoni S; Zani A; Muccioli F; Laderchi A; Rabini S; Antinori A; Vaia F; Nicastri E; Girardi E Clin Microbiol Infect; 2022 Dec; 28(12):1636-1643. PubMed ID: 35798146 [TBL] [Abstract][Full Text] [Related]
36. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. Cohen MJ; Oster Y; Moses AE; Spitzer A; Benenson S; JAMA Netw Open; 2022 Aug; 5(8):e2224657. PubMed ID: 35917125 [TBL] [Abstract][Full Text] [Related]
37. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073 [TBL] [Abstract][Full Text] [Related]
38. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Puhach O; Adea K; Hulo N; Sattonnet P; Genecand C; Iten A; Jacquérioz F; Kaiser L; Vetter P; Eckerle I; Meyer B Nat Med; 2022 Jul; 28(7):1491-1500. PubMed ID: 35395151 [TBL] [Abstract][Full Text] [Related]
39. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. Wu D; Ye Y; Tang L; Wang AB; Zhang R; Qian ZH; Wang FZ; Zheng H; Huang C; Lv XY; Wang HF; Zhang YY; Pan JJ; Li YF; Lu MX; Wang CS; Ma YT; An ZJ; Rodewald LE; Yin ZD; Wang XY; Wu ZY; Shao YM Emerg Microbes Infect; 2022 Dec; 11(1):1950-1958. PubMed ID: 35850623 [TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]